Results 11 to 20 of about 14,336,962 (399)
The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells
Haematologica, 2017 The development of inhibitory antibodies to therapeutic factor VIII is the major complication of replacement therapy in patients with hemophilia A. The first step in the initiation of the anti-factor VIII immune response is factor VIII interaction with ...
Bagirath Gangadharan +6 more
doaj +2 more sources
Haematologica, 2016 It has been proposed that von Willebrand factor might affect factor VIII immunogenicity by reducing factor VIII uptake by antigen presenting cells. Here we investigate the interaction of recombinant von Willebrand factor with immature monocyte-derived ...
Nicoletta Sorvillo +8 more
doaj +2 more sources
Haematologica, 2015 A large fraction of factor VIII in blood originates from liver sinusoidal endothelial cells although extrahepatic sources also contribute to plasma factor VIII levels.
Diego Zanolini +12 more
doaj +2 more sources
Haematologica, 2015 The rising incidence of neutralizing antibodies (inhibitors) against therapeutic factor VIII prompted the conduct of studies to answer the question as to whether this rise is related to the introduction of recombinant factor VIII products.
Johannes Oldenburg +2 more
doaj +2 more sources
Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients
Haematologica, 2013 Since 1981, the number of factor VIII units to infuse into patients with hemophilia A in order to achieve adequate circulating factor VIII levels has been calculated using the formula: [body weight(kg)×desired factor VIII increase(%)]/2, assuming a ...
Séverine Henrard +2 more
doaj +2 more sources
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
New England Journal of Medicine, 2021 BACKGROUND The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector dose.
Lindsey A. George +18 more
semanticscholar +1 more source
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
New England Journal of Medicine, 2020 BACKGROUND Factor VIII replacement products have improved the care of patients with hemophilia A, but the short half-life of these products affects the patients' quality of life. The half-life of recombinant factor VIII ranges from 15 to 19 hours because
B. Konkle +11 more
semanticscholar +1 more source
Successful elimination of factor VIII inhibitor using cyclosporin A [PDF]
, 2003 No abstract ...
Dykes +10 more
core +1 more source
BMJ, 1995 Patients with haemophilia A lack only factor VIII. Why give them anything else as replacement treatment? Previously the answer to this question was determined largely by the practical difficulty in separating factor VIII from fibrinogen, fibronectin, and immunoglobulins, so that concentrates contained 2000 U/mg respectively, but concentrates prepared ...
Michael Laffan, Edward G. D. Tuddenham
openaire +3 more sources
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
New England Journal of Medicine, 2016 BACKGROUND The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy.
F. Peyvandi +46 more
semanticscholar +1 more source